Pharvaris Study Reveals Treatment Gaps in Hereditary Angioedema Management
Event summary
- Pharvaris published a real-world analysis of HAE disease management in Advances in Therapy on October 5, 2026.
- The study evaluated 1,131 patients and 225 physicians across the US, Europe, and Japan between January 2023 and January 2024.
- Key findings include treatment satisfaction gaps driven by portability, administration route, efficacy, and adverse event risks.
- Patients prefer daily oral treatments over biweekly or monthly injections for long-term prophylaxis.
- Suboptimal adherence was linked to treatment burden, lack of availability, and pain associated with injectable treatments.
The big picture
The study underscores persistent disparities between guideline-recommended care and real-world HAE management, highlighting the need for treatments that balance efficacy with patient convenience. Pharvaris aims to capitalize on these insights to set a new standard in bradykinin-mediated angioedema care, addressing unmet needs in a competitive biopharmaceutical landscape.
What we're watching
- Treatment Innovation
- How Pharvaris will leverage these insights to develop more patient-friendly oral treatments.
- Regulatory Alignment
- Whether the identified gaps will prompt regulatory bodies to update HAE treatment guidelines.
- Market Differentiation
- The pace at which Pharvaris can differentiate its offerings based on real-world patient preferences.